公开(公告)号：US20110130296A1

公开(公告)日：2011-06-02

申请号：US12922651

申请日：2009-03-10

申请人： Christopher Benz ,  Laura Esserman ,  Frederic Waldman ,  Christina Yau

发明人： Christopher Benz ,  Laura Esserman ,  Frederic Waldman ,  Christina Yau

IPC分类号： C40B30/00 ,  C40B40/06 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158

摘要： The present invention relates to the identification of marker genes useful in the diagnosis and prognosis of clinically problematic subsets of primary breast cancers. More specifically, the invention relates to the identification of two sets of marker genes that are differentially expressed in and useful for the diagnosis and prognosis of subsets of hormone receptor-negative (HRneg; i.e., ER and PR negative) and triple-negative (Tneg; i.e., ER, PR and HER2 negative) primary breast cancers at highest risk for early metastatic relapse. The invention further provides methods for determining the best course of treatment for patients having one of these clinically problematic subsets of primary breast cancers. The invention also provides methods for identifying compounds that prevent or treat a subtype of breast cancer based on their ability to modulate the activity or expression level of one or more marker genes identified herein.

摘要翻译： 本发明涉及可用于诊断和预后的原发性乳腺癌临床问题亚群的标记基因的鉴定。 更具体地，本发明涉及两组标记基因的鉴定，所述两组标记基因差异表达并且可用于激素受体阴性（HRneg;即ER和PR阴性）和三阴性（Tneg）的子集的诊断和预后 ;即ER，PR和HER2阴性）原发性乳腺癌患有早期转移性复发的最高风险。 本发明还提供了确定患有这些临床上有问题的原发性乳腺癌亚型之一的患者的最佳治疗方案的方法。 本发明还提供了基于其调节本文鉴定的一种或多种标记基因的活性或表达水平的能力来鉴定预防或治疗乳腺癌亚型的化合物的方法。